Cargando…

Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014

Background. The purpose of this study was to assess the efficacy and tolerability of combined antiretroviral therapy (cART) in human immunodeficiency virus (HIV)-1 virologically suppressed patients who switched to rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) as a single-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cazanave, Charles, Reigadas, Sandrine, Mazubert, Cyril, Bellecave, Pantxika, Hessamfar, Mojgan, Le Marec, Fabien, Lazaro, Estibaliz, Peytavin, Gilles, Bruyand, Mathias, Fleury, Hervé, Dabis, François, Neau, Didier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438898/ https://www.ncbi.nlm.nih.gov/pubmed/26034768 http://dx.doi.org/10.1093/ofid/ofv018

Ejemplares similares

Severe Morbidity According to Sex in the Era of Combined Antiretroviral Therapy: The ANRS CO3 Aquitaine Cohort
por: Hessamfar, Mojgan, et al.
Publicado: (2014)

Incidence and Risk Factors for Severe Bacterial Infections in People Living with HIV. ANRS CO3 Aquitaine Cohort, 2000–2012
por: Collin, Amandine, et al.
Publicado: (2016)

A Low Level of Darunavir Resistance–Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort
por: Chaussade, Hélène, et al.
Publicado: (2020)

Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort’s QuAliV ancillary study
por: Barger, Diana, et al.
Publicado: (2020)

Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure
por: Vandenhende, Marie-Anne, et al.
Publicado: (2014)

Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort
por: Bonnet, F., et al.
Publicado: (2020)

Temporal trend of the first prescription of nevirapine: the ANRS CO3 Aquitaine Cohort, 1997-2008
por: Bruyand, M, et al.
Publicado: (2010)

Immunodeficiency, HIV RNA plasma viral load and risk of AIDS-defining and non-AIDS-defining neoplasia, ANRS CO3 Aquitaine Cohort (1998–2006)
por: Bruyand, M, et al.
Publicado: (2009)

Bacterial Pneumonia among HIV-Infected Patients: Decreased Risk After Tobacco Smoking Cessation. ANRS CO3 Aquitaine Cohort, 2000–2007
por: Bénard, Antoine, et al.
Publicado: (2010)

One year of SARS-CoV-2 circulation in the Nouvelle-Aquitaine region, February 2021–2022, France
por: Deroche, Luc, et al.
Publicado: (2023)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia
por: Taramasso, Lucia, et al.
Publicado: (2019)

Factors associated with poorer quality of life in people living with HIV in southwestern France in 2018–2020 (ANRS CO3 AQUIVIH-NA cohort: QuAliV study)
por: Barger, Diana, et al.
Publicado: (2023)

Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up
por: Charpentier, Charlotte, et al.
Publicado: (2015)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
por: Bernardini, Claudia, et al.
Publicado: (2013)

Tobacco, alcohol, cannabis, and illicit drug use and their association with CD4/CD8 cell count ratio in people with controlled HIV: a cross-sectional study (ANRS CO3 AQUIVIH-NA-QuAliV)
por: Devos, Sophie, et al.
Publicado: (2023)

Hepatite delta /
por: Fonseca, José Carlos Ferraz da
Publicado: (1993)

Hépatite alcoolique
por: Jugnundan, Sechiv, et al.
Publicado: (2023)

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide
por: Custodio, Joseph M., et al.
Publicado: (2017)

Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, ANRS CO3 Aquitaine Cohort, France, 2004–2012
por: Morlat, Philippe, et al.
Publicado: (2013)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: hospital-based cohort studies
por: Luz, Paula Mendes, et al.
Publicado: (2014)

Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
por: Wainberg, Mark A
Publicado: (2013)

Simultaneous Spectrophotometric Method for Determination of Emtricitabine and Tenofovir Disoproxil Fumarate in Three-Component Tablet Formulation Containing Rilpivirine Hydrochloride
por: Venkatesan, S., et al.
Publicado: (2014)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study
por: Falcon-Neyra, Lola, et al.
Publicado: (2016)

L'Hepatite Alcoolique Aigue
por: Bertrand, L.
Publicado: (1977)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans
por: Seneviratne, Herana Kamal, et al.
Publicado: (2020)

Edition Nationale
por: Hugo, Victor, 1802-1885
Publicado: (1887)

Edition Nationale
por: Hugo, Victor, 1802-1885
Publicado: (1885)

Hépatite auto-immune déclenchée après une hépatite aiguë grave à Epstein Barr virus
por: Montacer, Khaoula El, et al.
Publicado: (2020)

537 STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96
por: Creticos, Catherine, et al.
Publicado: (2014)

A comprehensive analysis of excess depressive disorder in women and men living with HIV in France compared to the general population
por: Hémar, Victor, et al.
Publicado: (2022)

New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
por: Patel, Nimish, et al.
Publicado: (2012)

Web-Based Module for the Collection of Electronic Patient-Reported Outcomes in People Living With HIV in Nouvelle Aquitaine, France: Usability Evaluation
por: Barger, Diana, et al.
Publicado: (2019)

Influenzapandemieplanung: Nationaler Influenzapandemieplan
Publicado: (2005)

Nationale Forschungsdateninfrastruktur (NFDI)
por: Hartl, Nathalie, et al.
Publicado: (2021)

Stability-Indicating HPLC Method for the Simultaneous Determination of HIV Tablet Containing Emtricitabine, Tenofovir Disoproxil Fumarate, and Rilpivirine Hydrochloride in Pharmaceutical Dosage Forms
por: Venkatesan, S., et al.
Publicado: (2014)

COVID-19 : pour une coordination nationale et européenne de la recherche
Publicado: (2020)

Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles
por: Tumiotto, Camille, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0r03ecegd7j9edounsv1cad7hf